Bengaluru doctors have successfully treated a 68-year-old man diagnosed with metastatic, Stage 4 gastric adenocarcinoma, reflecting the potential of molecular testing and highly personalised, risk-mitigated chemotherapy protocols.
The man was living with prevailing health challenges like morbid obesity (weighing 99 kilograms), diabetes, and coronary artery disease. He sought medical attention after experiencing progressive fatigue, anaemia, and melena (black, tarry stools indicating internal gastrointestinal bleeding).
An urgent upper gastrointestinal endoscopy performed by clinical teams revealed a massive, highly fragile ulcer proliferative tumour occupying a large portion of his stomach. The location and size of the growth carried a severe, immediate risk of life-threatening bleeding and stomach perforation. Additional staging procedures revealed that the high-grade carcinoma had metastasized into regional lymph nodes as well as two separate metastases within his liver, thereby establishing the disease as Stage 4.
With regard to the above-mentioned clinical challenges, traditional aggressive treatment regimens would not be an option due to the risks of causing lethal hemorrhage and cardiac collapse owing to his heart ailment.
A tailored treatment approach was planned rather than a standard one by the doctors at Apollo Hospitals Jayanagar. The man was put on a customised FLOT chemotherapy protocol comprising oxaliplatin, docetaxel, and capecitabine. With his vulnerable cardiovascular system and sensitive stomach in mind, the therapy commenced at a very low dose and increased with every subsequent cycle according to his tolerance to the medicine.
The pivotal aspect of his treatment came in the form of sophisticated molecular analysis of his tumour. Through genetic analysis, the oncologist discovered that the cancer was HER2 positive. It was this biological marker that helped him incorporate an agent known as Trastuzumab in the treatment strategy.
The results obtained were impressive. On subsequent imaging, there was considerable reduction in size of the primary stomach tumor, along with a regression of the two metastases located in the liver. Because of such an amazing response, the staging of his disease had been successfully changed; making him a surgical candidate.
In the next stage of management, the patient went through a very challenging surgery to get rid of the rest of the tumor. Notwithstanding his obesity and cardiovascular risks, he emerged a successful surgical candidate and was put on targeted therapy involving Trastuzumab maintenance for one year.
Following the aggressive intervention, the patient has made an exceptional recovery and remains in complete remission more than two and a half years later. Alongside beating the cancer, his physical health has undergone a massive transformation; his weight has dropped safely from 99 kg to 83 kg, and he now enjoys an active, high-quality lifestyle that seemed impossible at the time of his diagnosis.
Dr Poonam Maurya, senior consultant Medical Oncologist, Hematooncologist, and BMT and CAR-T Cell expert from Apollo Hospitals Jayanagar, said, “This case highlights three powerful lessons. First, Stage 4 cancer is not a single entity. Selected patients with limited metastatic disease can achieve exceptional outcomes when treated appropriately. Also, the concept of precision oncology is very important. Molecular testing and targeted therapies are increasingly changing the landscape of cancer treatment and improving survival outcomes. Third, age, obesity, diabetes, or cardiac comorbidities should not automatically deny patients access to potentially life-changing treatment. With careful planning, dose modification, multidisciplinary care, and personalized decision-making, even high-risk patients can derive significant benefit.”
Persistent gastrointestinal warning signs, including unexplained fatigue, chronic anemia, blood in the stool, or sudden weight loss, must never be ignored. They underlined that early diagnostic endoscopy, prompt oncological consultation, and early molecular testing of tumor tissues are vital to achieving successful, long-term remission in advanced cancers.
B'luru docs give new lease of life to man suffering from Stage 4 stomach cancer
